BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37463305)

  • 1. Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.
    Hofmeister MG; Zhong Y; Moorman AC; Samuel CR; Teshale EH; Spradling PR
    Clin Infect Dis; 2023 Dec; 77(12):1668-1675. PubMed ID: 37463305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
    Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
    Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
    Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
    Chu C; Gomes T; Antoniou T; Wong WWL; Janjua N; Guertin JR; Schwartz KL; Feld J; Kwong J; Tadrous M
    PLoS One; 2023; 18(8):e0284914. PubMed ID: 37552677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
    Kim D; Li AA; Gadiparthi C; Khan MA; Cholankeril G; Glenn JS; Ahmed A
    Gastroenterology; 2018 Oct; 155(4):1154-1163.e3. PubMed ID: 30009816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
    Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML
    J Viral Hepat; 2022 May; 29(5):366-374. PubMed ID: 35254695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
    Jung J; Du P; Feldman R; Kong L; Riley T
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
    Du P; Wang X; Kong L; Jung J
    Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
    Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
    JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C Treatment Initiation Among US Medicaid Enrollees.
    Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco R; Hutchings K; Wethington E; Talal A; Lloyd A; Dharia A; Wells M; Bao Y; Shapiro MF
    JAMA Netw Open; 2023 Aug; 6(8):e2327326. PubMed ID: 37540513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.
    Du P; Jung J; Kalidindi Y; Farrow K; Riley T; Whitener C
    J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):130-134. PubMed ID: 32011599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
    Yin X; Kong L; Du P; Jung J
    AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment.
    Wong RJ; Jain MK; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Thamer M
    Am J Gastroenterol; 2018 Sep; 113(9):1329-1338. PubMed ID: 29523864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 18. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
    Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
    J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C.
    Jiang X; Song HJ; Chang CY; Wilson D; Guo J; Lo-Ciganic WH; Park H
    Med Care; 2023 Feb; 61(2):81-86. PubMed ID: 36453625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.
    Du P; Wang X; Kong L; Riley T; Jung J
    Am J Prev Med; 2021 Feb; 60(2):285-293. PubMed ID: 33221144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.